Tempus AI (TEM) made its trading debut on the Nasdaq via an IPO. The stock has popped in Friday trading after opening at $37 per share. Market Domination Anchors Julie Hyman and Josh Lipton look at Tempus in the broader AI narrative
For more expert insight and the latest market action, click here to watch this full episode of Market Domination.
This post was written by Luke Carberry Mogan.
Video Transcript
Tempest A I making its Wall Street debut.
Trading started today on the NASDAQ, the company pricing its offering at $37 per share.
So this one was um an instrument so it makes it makes its debut.
Um They’re kind of they’re using A I to process medical data.
Um They’ve actually been around for some time, Julie, they were actually found in 2015, described their businesses creating intelligent diagnostics for precision medicine in terms of the financials posted revenue of 532 million in 2023.
That was up from 321 million the year earlier.
It looks like they’re still losing money that lost about roughly 200 million in 23.
Of course, not unusual for a tech company to go public.
Uh post losses and investors will often look through that, especially if you have A I in the name.
Yeah, although it’s become less typical, I feel like you have more companies more at a more mature level coming public and maybe posting profit.
But this not at that case.
It is, it, it sounds interesting what they do.
They connect your lab results to your personal clinical data to kind of analyze, I guess using A I.
So, you know, we’ll see uh how they continue to go.
They did rise as much as 18% at one point during the day.
But as we could see, they’re up about 10.5%.
Ceo Eric Lefkofsky also, by the way, co founder, Groupon, fact, interesting, very different business.
I don’t know what lessons he’s applying, but he must be applying some.
Hopefully he’ll come talk to us and we can ask him that’s a formal invitation to Eric.